|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:businessModel
|
acquiring biopharmaceutical royalties
specialty finance company
|
|
gptkbp:CEO
|
gptkb:Pablo_Legorreta
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focus
|
biopharmaceutical royalties
|
|
gptkbp:founded
|
1996
|
|
gptkbp:founder
|
gptkb:Pablo_Legorreta
|
|
gptkbp:headquarters_location
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Royalty Pharma
|
|
gptkbp:industry
|
finance
pharmaceuticals
|
|
gptkbp:IPODate
|
2020
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:mainActivity
|
funding innovation in life sciences
|
|
gptkbp:marketCap
|
over $15 billion (as of 2023)
|
|
gptkbp:notable_deal
|
gptkb:Pfizer_Ibrance_royalties
gptkb:Vertex_Pharmaceuticals_cystic_fibrosis_royalties
Alnylam Pharmaceuticals royalties
Biohaven Pharmaceuticals royalties
Epizyme royalties
Gilead Trodelvy royalties
|
|
gptkbp:notableInvestment
|
gptkb:Xtandi_royalties
Cystic fibrosis franchise royalties
Imbruvica royalties
Tysabri royalties
|
|
gptkbp:numberOfEmployees
|
approximately 50 (as of 2023)
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:RPRX
|
|
gptkbp:website
|
https://www.royaltypharma.com/
|
|
gptkbp:bfsParent
|
gptkb:Cathy_Engelbert
gptkb:General_Atlantic
|
|
gptkbp:bfsLayer
|
6
|